Indication: CNS Cancer
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After
Sub-indication: CNS Cancer
Drug Study
Principal Investigator: Renato LaRocca, M.D.Norton Cancer Institute
Sponsor: Orbus Therapeutic Inc
Learn more at ClinicalTrials.gov
Email for more information: CNS-NCIResearch@nortonhealthcare.org
